Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS35
PHASE 3 / 2-310
RECRUITING20
READOUTS ≤12 MONTHS14
READOUT SLIPPED >6 MO47%
Delay Index: of 15 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.2 months). See all sponsors →
Open Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on the live radar map → 📅 $6990.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SKB264 NCT05347134 |
P3 | Active, not recruiting | Triple Negative Breast Cancer | 254 | 2023-11-30 |
| SKB264 NCT05870319 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 376 | 2024-07-11 (-10 mo) |
| SKB264 NCT05351788 |
P2 | Recruiting | Non-small Cell Lung Cancer | 110 | 2026-08 (+36 mo) |
| SKB264 NCT06448312 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 406 | 2026-11 |
| A166 NCT06968585 |
P3 | Active, not recruiting | HER2-positive Breast Cancer | 365 | 2026-11-30 (+12 mo) |
| SKB264 NCT06711900 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 432 | 2026-12 |
| SKB264 NCT05631262 |
P2 | Active, not recruiting | Selected Subjects With Advanced Solid Tumors | 321 | 2026-12-30 (+26 mo) |
| KL590586 Capsule NCT05265091 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 414 | 2026-12-31 (+19 mo) |
| SKB264 NCT06081959 |
P3 | Recruiting | Metastatic Breast Cancer | 376 | 2026-12-31 (+9 mo) |
| SKB518 NCT07019675 |
P2 | Recruiting | Lung Carcinoma | 192 | 2027-02-20 (-4 mo) |
| SKB264 NCT06279364 |
P3 | Active, not recruiting | Triple Negative Breast Cancer | 537 | 2027-04 (+9 mo) |
| SKB264 NCT06670196 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 420 | 2027-05 |
| SKB571 for injection NCT07308106 |
P2 | Recruiting | Non-small Lung Cancer | 70 | 2027-06-30 |
| SKB264 NCT07071337 |
P3 | Recruiting | Metastatic Breast Cancer | 430 | 2027-07 |
| Sacituzumab Tirumotecan NCT07329322 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 30 | 2027-08-31 |
| SKB571 for injection NCT07564466 |
P2 | Recruiting | Gastrointestinal Tumors | 160 | 2027-08-31 |
| A166 NCT07299825 |
P2 | Recruiting | Her 2 Positive Breast Cancer | 40 | 2027-09-20 |
| KL-A167 NCT05294172 |
P3 | Active, not recruiting | Nasopharyngeal Carcinoma; Recurrent or Metastatic | 295 | 2027-12 (+42 mo) |
| SKB264+SKB118 NCT07854509 |
P2 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 110 | 2027-12-30 |
| SKB518 for injection NCT07448922 |
P2 | Recruiting | Advanced Gynecological Malignancies | 280 | 2027-12-31 |
| SKB264 NCT07341100 |
P2 | Active, not recruiting | Ovarian Epithelial Cancer | 20 | 2028-01 |
| SKB571 for injection NCT07230405 |
P2 | Recruiting | Lung Cancer (Non-Small Cell) | 295 | 2028-01-19 (+1 mo) |
| SKB571 NCT07814066 |
P2 | Not yet recruiting | Pancreatic Cancer | 30 | 2028-02-28 |
| Sacituzumab tirumotecan NCT07324629 |
P2 | Recruiting | Thymic Carcinoma | 30 | 2028-04 |
| SKB315 NCT07609667 |
P2 | Not yet recruiting | Gastroesophageal Junction Adenocarcinoma | 80 | 2028-06-30 |
| SKB264+SKB118 NCT07697586 |
P2 | Recruiting | NSCLC | 206 | 2028-08 |
| SKB571 NCT07668154 |
P2 | Recruiting | HNSCC | 120 | 2028-09-30 |
| SKB571 for injection NCT07622186 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 150 | 2028-12-31 |
| SKB500 NCT07700667 |
P2 | Recruiting | Esophageal Squamous Cell Carcinoma | 120 | 2028-12-31 |
| SKB500 Powder for Injection NCT07296809 |
P2 | Recruiting | Small Cell Lung Cancer | 80 | 2028-12-31 |
| SKB565 NCT07545265 |
P1/2 | Recruiting | Advanced Solid Tumors | 180 | 2029-03 |
| SKB118 Injection NCT07586943 |
P1/2 | Recruiting | Advanced Solid Tumors | 530 | 2029-12 |
| SKB105 for injection Monotherapy NCT07380386 |
P1/2 | Recruiting | Advanced Solid Tumors | 256 | 2029-12-31 |
| SKB103 for injection monotherapy NCT07459998 |
P1/2 | Recruiting | Advanced Solid Tumors | 277 | 2029-12-31 |
| SKB103 monotherapy NCT07774624 |
P1/2 | Not yet recruiting | Breast Cancer | 140 | 2029-12-31 |